Cargando…
The Unpluggable in Pursuit of the Undruggable: Tackling the Dark Matter of the Cancer Therapeutics Universe
The notion that targeted drugs can unplug gain-of-function tumor pathways has revitalized pharmaceutical research, but the survival benefits of this strategy have so far proven modest. A weakness of oncogene-blocking approaches is that they do not address the problem of cancer progression as selecte...
Autor principal: | Epstein, Richard J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3859984/ https://www.ncbi.nlm.nih.gov/pubmed/24377088 http://dx.doi.org/10.3389/fonc.2013.00304 |
Ejemplares similares
-
Therapeutic targeting of “undruggable” MYC
por: Llombart, Victor, et al.
Publicado: (2021) -
Drugging an undruggable pocket on KRAS
por: Kessler, Dirk, et al.
Publicado: (2019) -
Targeting STATs for cancer therapy: “Undruggable” no more
por: Frank, David A.
Publicado: (2012) -
KRAS mutation: from undruggable to druggable in cancer
por: Huang, Lamei, et al.
Publicado: (2021) -
Drugging the Undruggable: Advances on RAS Targeting in Cancer
por: Molina-Arcas, Miriam, et al.
Publicado: (2021)